Filing Flows › Lineage Cell Therapeutics (LCTX) › Q3 2025
Lineage Cell Therapeutics (LCTX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Lineage Cell Therapeutics (LCTX) reported revenue of $3.7M for the third quarter 2025 (Q3 2025), -3% from a year earlier and +33% from the quarter before. Operating margin was -102.9%, net loss $29.8M (808.3% of revenue).
Lineage Cell Therapeutics, Q3 2025: revenue $3.7M (-3% year over year), operating margin -102.9%, net loss $29.8M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | +33% | -3% |
| Operating profit | −$3.8M | — | — |
| Net earnings | −$29.8M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $3.7M in Q3 2025, down 3% year over year and up 33% from the previous quarter. Other Collaborative Revenue was the largest line at 48% of revenue. Upfront License Fees lost $1.6M year over year (down 48%), 1657% of the total change.
Operating costs exceeded revenue by $3.8M, an operating margin of -102.9%. Total costs fell 2% while revenue fell 3%. The quarter ended with a net loss of $29.8M, narrower than the previous quarter's $30.4M loss. Net interest and other expense of $26.0M was the main reason.
Operating cash flow was −$3.6M. Non-cash charges added back $178K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $24.8M. Capital expenditures of $12K exceeded it, leaving free cash flow of −$3.6M.
Questions
What was Lineage Cell Therapeutics' revenue in the third quarter 2025?
Lineage Cell Therapeutics (LCTX) reported revenue of $3.7M for the third quarter 2025 (Q3 2025), -3% from a year earlier and +33% from the quarter before.
Was Lineage Cell Therapeutics profitable in the third quarter 2025?
Operating loss was $3.8M (-102.9% of revenue) and net loss $29.8M.